Arnatar Therapeutics Named a BioSpace Top Life Sciences Startup to Watch
SAN DIEGO, CA, January 6, 2025 – Arnatar Therapeutics, a biotechnology company developing RNA-based therapies for severe and underserved diseases, today announced it’s inclusion in NextGen: Class of 2026, BioSpace’s annual list recognizing top life sciences startups to watch.
Arnatar Therapeutics is advancing a proprietary RNA platform designed to precisely modulate gene expression through a dual-modality approach that enables both silencing of pathogenic drivers and restoration of essential protein function. The company’s DARGER™ platform supports a broad pipeline spanning cardiometabolic, liver, kidney, and central nervous system diseases, addressing areas of high unmet medical need through programmable RNA therapeutics.
The NextGen: Class of 2026 list showcases 15 innovative organizations demonstrating exciting potential. BioSpace’s editorial team analyzed multiple factors: financing, collaborations, pipeline, growth potential and innovation. This year’s list includes top-scoring organizations that launched with Series A funding. This is the 12th year BioSpace has highlighted the most anticipated new biopharma companies from across the U.S.
Arnatar is thrilled to have been included in this year’s list.
“Being recognized by BioSpace as a startup to watch underscores the strength of our science and the promise of our dual-modality RNA platform,” said Yanfeng Wang, Ph.D., Chief Operating Officer of Arnatar Therapeutics. “We are building RNA medicines that expand what’s possible for patients by not only silencing disease-causing genes but, more importantly, also restoring critical protein expression where current approaches fall short.”
About Arnatar Therapeutics
Arnatar Therapeutics is a clinical-stage biotechnology company redefining the possibilities of RNA medicine. With its proprietary DARGER™ platform, Arnatar uniquely integrates best-in-class siRNA gene silencing with first-in-class antisense oligonucleotides (ASOs) that upregulate protein expression. This dual-modality platform allows Arnatar to develop RNA medicines that either silence harmful disease drivers through siRNA or restore essential protein function through up-regulating ASOs, opening new therapeutic possibilities for previously untreatable conditions. The company’s pipeline spans across cardiometabolic, liver, kidney, and central nervous system diseases, targeting areas of high unmet medical need. Founded by leaders in RNA therapeutics and backed by leading biotech investors, Arnatar is committed to translating RNA innovation into life-changing, programmable medicines to improve patients’ lives worldwide.
About BioSpace
BioSpace is the hub for life sciences news and jobs. We provide essential insights, opportunities, and tools to connect innovative organizations and talented professionals who advance health and quality of life across the globe. Learn more and subscribe at www.biospace.com.
InvestorContact
Chris Nardo
LifeSci Advisors, LLC
cnardo@lifesciadvisors.com
646-517-2499
BioSpace Contact
Chantal Dresner
VP of Marketing, BioSpace
chantal.dresner@biospace.com